{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:51:03Z","timestamp":1791258663967,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004214","name":"Pamukkale \u00dcniversitesi","doi-asserted-by":"publisher","award":["2022SABE008"],"award-info":[{"award-number":["2022SABE008"]}],"id":[{"id":"10.13039\/501100004214","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"DOI":"10.1186\/s12906-026-05456-6","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T13:22:54Z","timestamp":1783776174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative evaluation of the effects of Silymarin on the metastatic characteristics of MCF-7 and MDA-MB-231 breast cancer cells with two-dimensional and three-dimensional culture methods"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3250-6113","authenticated-orcid":false,"given":"Tu\u011f\u00e7e","family":"Alada\u011f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0027-5138","authenticated-orcid":false,"given":"Fatma","family":"Firat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8731-0631","authenticated-orcid":false,"given":"H\u00fclya","family":"\u00c7etin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8550-793X","authenticated-orcid":false,"given":"Evrim Suna","family":"Arikan S\u00f6ylemez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"5456_CR1","doi-asserted-by":"publisher","unstructured":"Duval K, Grover H, Han LH, Mou Y, Pegoraro AF, Fredberg J, et al. Modeling physiological events in 2D vs. 3D cell culture. Physiology. 2017. https:\/\/doi.org\/10.1152\/physiol.00036.2016.","DOI":"10.1152\/physiol.00036.2016"},{"key":"5456_CR2","doi-asserted-by":"publisher","DOI":"10.1089\/ten.tea.2008.0131","author":"JA Burdick","year":"2009","unstructured":"Burdick JA, Vunjak-Novakovic G. Engineered microenvironments for controlled stem cell differentiation. Tissue Eng Part A. 2009. https:\/\/doi.org\/10.1089\/ten.tea.2008.0131.","journal-title":"Tissue Eng Part A"},{"key":"5456_CR3","doi-asserted-by":"publisher","unstructured":"Huang Z, Yu P, Tang J. Characterization of triple-negative breast cancer MDA-MB-231 cell spheroid model. Onco Targets Ther. 2020;13. https:\/\/doi.org\/10.2147\/OTT.S249756.","DOI":"10.2147\/OTT.S249756"},{"key":"5456_CR4","doi-asserted-by":"publisher","unstructured":"Singh M, Close DA, Mukundan S, Johnston PA, Sant S. Production of Uniform 3D Microtumors in Hydrogel Microwell Arrays for Measurement of Viability, Morphology, and Signaling Pathway Activation. Assay Drug Dev Technol. 2015;13(9). https:\/\/doi.org\/10.1089\/adt.2015.662.","DOI":"10.1089\/adt.2015.662"},{"key":"5456_CR5","doi-asserted-by":"publisher","unstructured":"Wang X lu, Lin F lan, Xu W, Wang C, Wang Q qi, Jiang RW. Silybin B exerts protective effect on cisplatin-induced neurotoxicity by alleviating DNA damage and apoptosis. J Ethnopharmacol. 2022;288. https:\/\/doi.org\/10.1016\/j.jep.2021.114938.","DOI":"10.1016\/j.jep.2021.114938"},{"key":"5456_CR6","doi-asserted-by":"publisher","DOI":"10.1517\/17460441.2015.1009442","author":"A Villasante","year":"2015","unstructured":"Villasante A, Vunjak-Novakovic G. Tissue-engineered models of human tumors for cancer research. Expert Opin Drug Discov. 2015. https:\/\/doi.org\/10.1517\/17460441.2015.1009442.","journal-title":"Expert Opin Drug Discov"},{"key":"5456_CR7","doi-asserted-by":"publisher","unstructured":"Sokolova V, Rojas-S\u00e1nchez L, Bia\u0142as N, Schulze N, Epple M. Calcium phosphate nanoparticle-mediated transfection in 2D and 3D mono- and co-culture cell models. Acta Biomater. 2019;84. https:\/\/doi.org\/10.1016\/j.actbio.2018.11.051.","DOI":"10.1016\/j.actbio.2018.11.051"},{"key":"5456_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01296-5","author":"L Yin","year":"2020","unstructured":"Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020. https:\/\/doi.org\/10.1186\/s13058-020-01296-5.","journal-title":"Breast Cancer Res"},{"key":"5456_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112358","author":"O Treeck","year":"2020","unstructured":"Treeck O, Sch\u00fcler-Toprak S, Ortmann O. Estrogen actions in triple-negative breast cancer. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9112358.","journal-title":"Cells"},{"key":"5456_CR10","doi-asserted-by":"publisher","unstructured":"Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013;31(31). https:\/\/doi.org\/10.1200\/jco.2013.50.9984.","DOI":"10.1200\/jco.2013.50.9984"},{"key":"5456_CR11","doi-asserted-by":"publisher","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15). https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3045.","DOI":"10.1158\/1078-0432.CCR-06-3045"},{"key":"5456_CR12","doi-asserted-by":"publisher","unstructured":"Martinotti S, Ranzato E. Scratch wound healing assay. In: Methods in Molecular Biology. 2020. https:\/\/doi.org\/10.1007\/7651_2019_259.","DOI":"10.1007\/7651_2019_259"},{"key":"5456_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2020.07.003","author":"B Bakir","year":"2020","unstructured":"Bakir B, Chiarella AM, Pitarresi JR, Rustgi AK. EMT, MET, Plasticity, and Tumor Metastasis. Trends Cell Biol. 2020. https:\/\/doi.org\/10.1016\/j.tcb.2020.07.003.","journal-title":"Trends Cell Biol"},{"key":"5456_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.08.009","author":"M Singh","year":"2018","unstructured":"Singh M, Yelle N, Venugopal C, Singh SK. EMT: Mechanisms and therapeutic implications. Pharmacol Ther. 2018. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.08.009.","journal-title":"Pharmacol Ther"},{"key":"5456_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2015.10.029","author":"K Burridge","year":"2016","unstructured":"Burridge K, Guilluy C. Focal adhesions, stress fibers and mechanical tension. Exp Cell Res. 2016. https:\/\/doi.org\/10.1016\/j.yexcr.2015.10.029.","journal-title":"Exp Cell Res"},{"key":"5456_CR16","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9176357","author":"Z Cesarz","year":"2016","unstructured":"Cesarz Z, Tamama K. Spheroid Culture of Mesenchymal Stem Cells. Stem Cells Int. 2016. https:\/\/doi.org\/10.1155\/2016\/9176357.","journal-title":"Stem Cells Int"},{"key":"5456_CR17","doi-asserted-by":"publisher","unstructured":"Pasztorek M, Rossmanith E, Mayr C, Hauser F, Jacak J, Ebner A, et al. Influence of Platelet Lysate on 2D and 3D Amniotic Mesenchymal Stem Cell Cultures. Front Bioeng Biotechnol. 2019;7. https:\/\/doi.org\/10.3389\/fbioe.2019.00338.","DOI":"10.3389\/fbioe.2019.00338"},{"key":"5456_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2012.08.009","author":"MA McNiven","year":"2013","unstructured":"McNiven MA. Breaking away: Matrix remodeling from the leading edge. Trends Cell Biol. 2013. https:\/\/doi.org\/10.1016\/j.tcb.2012.08.009.","journal-title":"Trends Cell Biol"},{"key":"5456_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.06.010","author":"AJ Ridley","year":"2011","unstructured":"Ridley AJ. Life at the leading edge. Cell. 2011. https:\/\/doi.org\/10.1016\/j.cell.2011.06.010.","journal-title":"Cell"},{"key":"5456_CR20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39104","author":"R Kalluri","year":"2009","unstructured":"Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Investig. 2009. https:\/\/doi.org\/10.1172\/JCI39104.","journal-title":"J Clin Investig"},{"key":"5456_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604662","author":"S Potenta","year":"2008","unstructured":"Potenta S, Zeisberg E, Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer. 2008. https:\/\/doi.org\/10.1038\/sj.bjc.6604662.","journal-title":"Br J Cancer"},{"key":"5456_CR22","doi-asserted-by":"publisher","unstructured":"Nistic\u00f2 P, Bissell MJ, Radisky DC. Epithelial-mesenchymal transition: General principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. Cold Spring Harb Perspect Biol. 2012;4(2). https:\/\/doi.org\/10.1101\/cshperspect.a011908.","DOI":"10.1101\/cshperspect.a011908"},{"key":"5456_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.03.053","author":"K Ramasamy","year":"2008","unstructured":"Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett. 2008. https:\/\/doi.org\/10.1016\/j.canlet.2008.03.053.","journal-title":"Cancer Lett"},{"key":"5456_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.6470","author":"T Hosseinabadi","year":"2019","unstructured":"Hosseinabadi T, Lorigooini Z, Tabarzad M, Salehi B, Rodrigues CF, Martins N, et al. Silymarin antiproliferative and apoptotic effects: Insights into its clinical impact in various types of cancer. Phytother Res. 2019. https:\/\/doi.org\/10.1002\/ptr.6470.","journal-title":"Phytother Res"},{"key":"5456_CR25","doi-asserted-by":"publisher","unstructured":"Stoellinger HM, Alexanian AR. Modifications to the Transwell Migration\/Invasion Assay Method That Eases Assay Performance and Improves the Accuracy. Assay Drug Dev Technol. 2022;20(2). https:\/\/doi.org\/10.1089\/adt.2021.140.","DOI":"10.1089\/adt.2021.140"},{"key":"5456_CR26","doi-asserted-by":"publisher","unstructured":"Karadeniz T, Cavuso\u01e7lu T, Turkmen E, Uyanikgil Y, Karadeniz M, Akdemir O, et al. Experimental comparison of protective characteristics of enalapril and trimetazidine in diabetic nephropathy. Ren Fail. 2014;36(8). https:\/\/doi.org\/10.3109\/0886022X.2014.930331.","DOI":"10.3109\/0886022X.2014.930331"},{"key":"5456_CR27","doi-asserted-by":"publisher","unstructured":"F\u0131rat F, \u00d6zg\u00fcl M, T\u00fcrk\u00f6z Uluer E, Inan S. Effects of caffeic acid phenethyl ester (CAPE) on angiogenesis, apoptosis and oxidat\u0131ve stress \u0131n various cancer cell lines. Biotech Histochem. 2019;94(7). https:\/\/doi.org\/10.1080\/10520295.2019.1589574.","DOI":"10.1080\/10520295.2019.1589574"},{"key":"5456_CR28","doi-asserted-by":"publisher","unstructured":"Seymour L, Bezwoda WR. Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators. Br J Cancer. 1993;68(2). https:\/\/doi.org\/10.1038\/bjc.1993.339.","DOI":"10.1038\/bjc.1993.339"},{"key":"5456_CR29","doi-asserted-by":"publisher","unstructured":"Tuli HS, Mittal S, Aggarwal D, Parashar G, Parashar NC, Upadhyay SK, et al. Path of Silibinin from diet to medicine: A dietary polyphenolic flavonoid having potential anti-cancer therapeutic significance. Semin Cancer Biol. 2021;73. https:\/\/doi.org\/10.1016\/j.semcancer.2020.09.014.","DOI":"10.1016\/j.semcancer.2020.09.014"},{"key":"5456_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212200","author":"O Habanjar","year":"2021","unstructured":"Habanjar O, Diab-Assaf M, Caldefie-Chezet F, Delort L. 3D cell culture systems: Tumor application, advantages, and disadvantages. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222212200.","journal-title":"Int J Mol Sci"},{"key":"5456_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121620","author":"NE Ryu","year":"2019","unstructured":"Ryu NE, Lee SH, Park H. Spheroid culture system methods and applications for mesenchymal stem cells. Cells. 2019. https:\/\/doi.org\/10.3390\/cells8121620.","journal-title":"Cells"},{"key":"5456_CR32","doi-asserted-by":"publisher","unstructured":"Abdollahi P, Ebrahimi M, Motamed N, Samani FS. Silibinin affects tumor cell growth because of reduction of stemness properties and induction of apoptosis in 2D and 3D models of MDA-MB-468. Anticancer Drugs. 2014;26(5). https:\/\/doi.org\/10.1097\/CAD.0000000000000205.","DOI":"10.1097\/CAD.0000000000000205"},{"key":"5456_CR33","doi-asserted-by":"publisher","unstructured":"Boo L, Ho WY, Ali NM, Yeap SK, Ky H, Chan KG, et al. Phenotypic and microRNA transcriptomic profiling of the MDA-MB-231 spheroid- enriched CSCs with comparison of MCF- 7 microRNA profiling dataset. PeerJ. 2017;2017(7). https:\/\/doi.org\/10.7717\/peerj.3551.","DOI":"10.7717\/peerj.3551"},{"key":"5456_CR34","doi-asserted-by":"publisher","unstructured":"Yazdi Rouholamini SE, Moghassemi S, Maharat Z, Hakamivala A, Kashanian S, Omidfar K. Effect of silibinin-loaded nano-niosomal coated with trimethyl chitosan on miRNAs expression in 2D and 3D models of T47D breast cancer cell line. Artif Cells Nanomed Biotechnol. 2018;46(3). https:\/\/doi.org\/10.1080\/21691401.2017.1326928.","DOI":"10.1080\/21691401.2017.1326928"},{"key":"5456_CR35","doi-asserted-by":"publisher","DOI":"10.1089\/adt.2014.573","author":"R Edmondson","year":"2014","unstructured":"Edmondson R, Broglie JJ, Adcock AF, Yang L. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014. https:\/\/doi.org\/10.1089\/adt.2014.573.","journal-title":"Assay Drug Dev Technol"},{"key":"5456_CR36","doi-asserted-by":"publisher","unstructured":"Breslin S, O\u2019Driscoll L. The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance. Oncotarget. 2016;7(29). https:\/\/doi.org\/10.18632\/oncotarget.9935.","DOI":"10.18632\/oncotarget.9935"},{"key":"5456_CR37","doi-asserted-by":"publisher","unstructured":"Kim SH, Choo GS, Yoo ES, Woo JS, Lee JH, Han SH, et al. Silymarin inhibits proliferation of human breast cancer cells via regulation of the MAPK signaling pathway and induction of apoptosis. Oncol Lett. 2021;21(6). https:\/\/doi.org\/10.3892\/ol.2021.12753.","DOI":"10.3892\/ol.2021.12753"},{"key":"5456_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jff.2022.105384","author":"Y Wang","year":"2023","unstructured":"Wang Y, Yuan AJ, Wu YJ, Wu LM, Zhang L. Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations. J Functional Foods. 2023. https:\/\/doi.org\/10.1016\/j.jff.2022.105384.","journal-title":"J Functional Foods"},{"key":"5456_CR39","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2023.93","author":"A Nikdouz","year":"2023","unstructured":"Nikdouz A, Orso F. Emerging roles of 3D-culture systems in tackling tumor drug resistance. Cancer Drug Resist. 2023. https:\/\/doi.org\/10.20517\/cdr.2023.93.","journal-title":"Cancer Drug Resist"},{"key":"5456_CR40","doi-asserted-by":"publisher","unstructured":"Chen G, Liu W, Yan B. Breast Cancer MCF-7 Cell Spheroid Culture for Drug Discovery and Development. J Cancer Ther. 2022;13(03). https:\/\/doi.org\/10.4236\/jct.2022.133009.","DOI":"10.4236\/jct.2022.133009"},{"key":"5456_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00006","author":"SA Langhans","year":"2018","unstructured":"Langhans SA. Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front Pharmacol. 2018. https:\/\/doi.org\/10.3389\/fphar.2018.00006.","journal-title":"Front Pharmacol"},{"key":"5456_CR42","doi-asserted-by":"publisher","unstructured":"Lashgarian HE, Adamii V, Ghorbanzadeh V, Chodari L, Kamali F, Akbari S, et al. Silibinin Inhibit Cell Migration through Downregulation of RAC1 Gene Expression in Highly Metastatic Breast Cancer Cell Line. Drug Res. 2020;70(10). https:\/\/doi.org\/10.1055\/a-1223-1734.","DOI":"10.1055\/a-1223-1734"},{"key":"5456_CR43","doi-asserted-by":"publisher","unstructured":"Sun HP, Su JH, Meng QS, Yin Q, Zhang ZW, Yu HJ, et al. Silibinin and indocyanine green-loaded nanoparticles inhibit the growth and metastasis of mammalian breast cancer cells in vitro. Acta Pharmacol Sin. 2016;37(7). https:\/\/doi.org\/10.1038\/aps.2016.20.","DOI":"10.1038\/aps.2016.20"},{"key":"5456_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071587","author":"GD Marconi","year":"2021","unstructured":"Marconi GD, Fonticoli L, Rajan TS, Pierdomenico SD, Trubiani O, Pizzicannella J, et al. Epithelial-mesenchymal transition (Emt): The type-2 emt in wound healing, tissue regeneration and organ fibrosis. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10071587.","journal-title":"Cells"},{"key":"5456_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20081933","author":"B Sousa","year":"2019","unstructured":"Sousa B, Pereira J, Paredes J. The crosstalk between cell adhesion and cancer metabolism. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20081933.","journal-title":"Int J Mol Sci"},{"key":"5456_CR46","doi-asserted-by":"publisher","unstructured":"Manuel Iglesias J, Beloqui I, Garcia-Garcia F, Leis O, Vazquez-Martin A, Eguiara A, et al. Mammosphere Formation in Breast Carcinoma Cell Lines Depends upon Expression of E-cadherin. PLoS One. 2013;8(10). https:\/\/doi.org\/10.1371\/journal.pone.0077281.","DOI":"10.1371\/journal.pone.0077281"},{"key":"5456_CR47","doi-asserted-by":"publisher","DOI":"10.1098\/rsif.2016.0877","author":"X Cui","year":"2017","unstructured":"Cui X, Hartanto Y, Zhang H. Advances in multicellular spheroids formation. J R Soc Interface. 2017. https:\/\/doi.org\/10.1098\/rsif.2016.0877.","journal-title":"J R Soc Interface"},{"key":"5456_CR48","doi-asserted-by":"publisher","unstructured":"Sameri S, Saidijam M, Bahreini F, Najafi R. Cancer Chemopreventive Activities of Silibinin on Colorectal Cancer through Regulation of E-Cadherin\/\u03b2-Catenin Pathway. Nutr Cancer. 2021;73(8). https:\/\/doi.org\/10.1080\/01635581.2020.1800764.","DOI":"10.1080\/01635581.2020.1800764"},{"key":"5456_CR49","doi-asserted-by":"publisher","unstructured":"Maleki N, Yavari N, Ebrahimi M, Faisal Faiz A, Khosh Ravesh R, Sharbati A, et al. Silibinin exerts anti-cancer activity on human ovarian cancer cells by increasing apoptosis and inhibiting epithelial-mesenchymal transition (EMT). Gene. 2022;823. https:\/\/doi.org\/10.1016\/j.gene.2022.146275.","DOI":"10.1016\/j.gene.2022.146275"},{"key":"5456_CR50","doi-asserted-by":"publisher","unstructured":"Si L, Fu J, Liu W, Hayashi T, Nie Y, Mizuno K, et al. Silibinin inhibits migration and invasion of breast cancer MDA-MB-231 cells through induction of mitochondrial fusion. Mol Cell Biochem. 2020;463(1\u20132). https:\/\/doi.org\/10.1007\/s11010-019-03640-6.","DOI":"10.1007\/s11010-019-03640-6"},{"key":"5456_CR51","doi-asserted-by":"publisher","unstructured":"Kim S, Jeon M, Lee J, Han J, Oh SJ, Jung T, et al. Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells. Oncol Rep. 2014;32(5). https:\/\/doi.org\/10.3892\/or.2014.3450.","DOI":"10.3892\/or.2014.3450"},{"key":"5456_CR52","doi-asserted-by":"publisher","unstructured":"Saitoh M. Involvement of partial EMT in cancer progression. The Journal of Biochemistry. 2018;164(4). https:\/\/doi.org\/10.1093\/jb\/mvy047.","DOI":"10.1093\/jb\/mvy047"},{"key":"5456_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.44","author":"T Shibue","year":"2017","unstructured":"Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017. https:\/\/doi.org\/10.1038\/nrclinonc.2017.44.","journal-title":"Nat Rev Clin Oncol"},{"key":"5456_CR54","doi-asserted-by":"publisher","unstructured":"Humphries MJ, Obara M, Olden K, Yamada KM. Role of fibronectin in adhesion, migration, and metastasis. Cancer Invest. 1989;7(4). https:\/\/doi.org\/10.3109\/07357908909039866.","DOI":"10.3109\/07357908909039866"},{"key":"5456_CR55","doi-asserted-by":"publisher","unstructured":"Armstrong PB, Armstrong MT. Intercellular invasion and the organizational stability of tissues: A role for fibronectin. Biochim Biophys Acta Rev Cancer. 2000;1470(2). https:\/\/doi.org\/10.1016\/S0304-419X(00)00003-2.","DOI":"10.1016\/S0304-419X(00)00003-2"},{"key":"5456_CR56","doi-asserted-by":"publisher","unstructured":"Meng XN, Jin Y, Yu Y, Bai J, Liu GY, Zhu J, et al. Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br J Cancer. 2009;101(2). https:\/\/doi.org\/10.1038\/sj.bjc.6605154.","DOI":"10.1038\/sj.bjc.6605154"},{"key":"5456_CR57","doi-asserted-by":"publisher","unstructured":"Dastpeyman M, Motamed N, Azadmanesh K, Mostafavi E, Kia V, Jahanian-Najafabadi A, et al. Inhibition of silibinin on migration and adhesion capacity of human highly metastatic breast cancer cell line, MDA-MB-231, by evaluation of \u03b21-integrin and downstream molecules, Cdc42, Raf-1 and D4GDI. Med Oncol. 2012;29(4). https:\/\/doi.org\/10.1007\/s12032-011-0113-8.","DOI":"10.1007\/s12032-011-0113-8"},{"key":"5456_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29982","author":"QP Hu","year":"2016","unstructured":"Hu QP, Kuang JY, Yang QK, Bian XW, Yu SC. Beyond a tumor suppressor: Soluble E-cadherin promotes the progression of cancer. Int J Cancer. 2016. https:\/\/doi.org\/10.1002\/ijc.29982.","journal-title":"Int J Cancer"},{"key":"5456_CR59","doi-asserted-by":"publisher","unstructured":"Kim S, Kim SH, Hur SM, Lee SK, Kim WW, Kim JS, et al. Silibinin prevents TPA-induced MMP-9 expression by down-regulation of COX-2 in human breast cancer cells. J Ethnopharmacol. 2009;126(2). https:\/\/doi.org\/10.1016\/j.jep.2009.08.032.","DOI":"10.1016\/j.jep.2009.08.032"},{"key":"5456_CR60","doi-asserted-by":"publisher","unstructured":"Byun HJ, Darvin P, Kang DY, Sp N, Joung YH, Park JH, et al. Silibinin downregulates MMP2 expression via Jak2\/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells. Oncol Rep. 2017;37(6). https:\/\/doi.org\/10.3892\/or.2017.5588.","DOI":"10.3892\/or.2017.5588"},{"key":"5456_CR61","doi-asserted-by":"publisher","unstructured":"Kim S, Han J, Jeon M, You D, Lee J, Kim HJ, et al. Silibinin inhibits triple negative breast cancer cell motility by suppressing TGF-\u03b22 expression. Tumor Biol. 2016;37(8). https:\/\/doi.org\/10.1007\/s13277-016-5000-7.","DOI":"10.1007\/s13277-016-5000-7"},{"key":"5456_CR62","doi-asserted-by":"publisher","unstructured":"Lu W, Lin C, King TD, Chen H, Reynolds RC, Li Y. Silibinin inhibits Wnt\/\u03b2-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells. Cell Signal. 2012;24(12). https:\/\/doi.org\/10.1016\/j.cellsig.2012.07.009.","DOI":"10.1016\/j.cellsig.2012.07.009"},{"key":"5456_CR63","doi-asserted-by":"publisher","unstructured":"Binienda A, Ziolkowska S, Pluciennik E. The Anticancer Properties of Silibinin: Its Molecular Mechanism and Therapeutic Effect in Breast Cancer. Anticancer Agents Med Chem. 2019;20(15). https:\/\/doi.org\/10.2174\/1871520620666191220142741.","DOI":"10.2174\/1871520620666191220142741"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-026-05456-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-026-05456-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-026-05456-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:09:00Z","timestamp":1791256140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12906-026-05456-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5456"],"URL":"https:\/\/doi.org\/10.1186\/s12906-026-05456-6","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"287"}}